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A NEW COMPLICATION OF STEM CELL TRANSPLAN-
TATION: MEASLES INCLUSION BODY ENCEPHALITIS
Jacobsohn DA*, Freeman AF, Kletzel M, Bellini WJ,
de Leon G, Shulman ST, Duerst R; Children’s Memo-
rial Hospital, Northwestern University, Feinberg
School of Medicine, Chicago, IL, USA
Measles virus is associated with 3 CNS syndromes:
acute encephalitis, subacute sclerosing panen-
cephalitis, and measles inclusion body encephalitis
(MIBE). MIBE typically occurs in immunocompro-
mised hosts within 1 year of measles infection or
exposure. A 13-year-old Mexican-American male
underwent a 6/6 HLA-matched-unrelated-donor
stem cell transplant (SCT) for chronic granulo-
matous disease. Immunoablative cytoreduction
included ﬂudarabine (180mg/m2), busulfan
(6.4mg/kg), and ATG. Graft-versus-host disease
(GVHD) prophylaxis with CSA/MMF. Biopsy-conﬁrmed
GVHD requiring systemic steroids developed on day
+15. On day +38 he developed seizures, involving
his left hand, which after a few days became gen-
eralized clinically and on EEG. Subclinical seizures
persisted despite phenobarbital levels greater than
300mg/dl. A mild CSF pleocytosis was present and
serial brain MRIs showed signal abnormalities in
both frontal lobes and the right temporal lobe.
After extensive negative serum and CSF testing,
brain biopsy was performed, which demonstrated
inclusion bodies with numerous paramyxovirus-like
structures seen by electron microscopy. PCR was
positive for wild-type measles virus, genotype D3.
Skin biopsy was negative for measles by PCR and
immunohistochemistry. Despite IV ribavirin ther-
apy, the patient expired 52 days after seizure
onset. This case resembles reported MIBE with its
presentation of afebrile focal, intractable seizures
(epilepsia partialis continua) and the characteris-
tic neuropathologic ﬁndings, but is unusual without
apparent measles exposure. Neither the patient
nor the donor had history of measles infection (the
donor’s stem cells were negative for measles by
PCR), measles exposure, or recent measles vacci-
nation. Neither had traveled to the Western Paciﬁc
where the D3 genotype is endemic. Although the
patient lived in Chicago (year of birth 1989) during
the epidemic of 1989—91 when D3 genotype was
endemic, previous cases of MIBE have not been
associated with such a long dormancy period. Our
patient is the 1st SCT recipient to have developed
MIBE and demonstrates the need for early brain
biopsy in immunocompromised patients with en-
cephalitis. This case raises the possibility of a long
period of dormancy from acute measles infection
to onset of MIBE.
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RITUXIMAB FOR PROPHYLAXIS OF EBV REACTIVA-
TION FOLLOWING HSCT IN PATIENTS WITH INHER-
ITED METABOLIC STORAGE DISEASES
Rossi MR, Longoni D*, Corti P, Balduzzi A, Dassi M,
Perseghin P, Gaipa G, Biondi A, Parini R, Sersale G,
Sessa M, Bertagnolio B, Uziel G, Uderzo C, Rovelli
A; MOMIN: Monza-Milano Network for Lysosomal and
Peroxisomal Diseases, Italy Pediatric Bone Marrow
Transplantation Center, Monza, Italy
GvHD has been correlated with a poorer neu-
ropsychological outcome in patients with inher-
ited metabolic storage diseases (IMSD), therefore
we included T-cell depletion by MACS technology
(TCD) in the procedure for these patients. Due to
the residual B-cell amount after two-step negative
selection (1 HSCT in this series) and the increased
number of B-cells in the ﬁnal product after the
T-cell addback following positive selection (the
other 11 HSCTs) (see Bone Marrow Transplant 2003;
31, 857—860), since 1999 a rituximab single dose on
day +3 was included in the treatment plan to carry
out a B-cell depletion in vivo to prevent EBV-PTLD.
Ten consecutive patients with different IMSD who
underwent 12 HSCTs (11 unrelated, 6 of them with
some degree of mismatching, and 1 related donor;
age at HSCT 1.2 to 32.4 years) were scheduled
to receive the anti-CD20 monoclonal antibody.
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Rituximab was administered following 11 HSCTs to
9 pts. and not to 1 for lack of parents consent.
Conditioning regimen included BuCy (7) or FluBuCy
(4) or TTCy (1) + ATG. All patients were monitored
weekly for EBV reactivation by quantitative PCR.
Engraftment occurred in all cases from day +10
to +15; 2 pts. who rejected, at +257 and +343
days, respectively, underwent successfully to a 2nd
HSCT from a different unrelated donor. The median
number of cells infused (x106/kg) was: CD34+ 5.6,
CD3+ 0.35 and 1.0 (at 1st and 2nd HSCT, respec-
tively). Only 1 pt. developed grade I acute skin
GvHD and 2 pts. limited chronic GvHD. One pt.
died; at a median follow-up of 2.8 years (0.8, 4.1)
9/10 pts. are alive with complete (8 pts.) or partial
(1 pt.) chimerism (70% donor); 7/9 with improved
neuropsychological function and 2 with stable dis-
ease but some disabilities (negative myoclonus)
developed after HSCT as a result of the primary
damage. None of the pts. developed EBV reacti-
vation, with the surprising exception of the only
pt. who did not receive rituximab as prophylaxis
and who was at that point (+71 days) successfully
treated with the anti-CD20 antibody (2 infusions).
Only 2 pts. have not yet recovered CD19+ cell
count: the one who developed EBV reactivation
and one who is only 9 months after HSCT. We used
rituximab empirically thinking it reasonable; due to
the rarity of IMSD and the limited number of such
a procedure/manipulation at our center, a speciﬁc
study was not feasible. Our observation is intrigu-
ing and prompts for randomized studies in settings
where a higher number of pts. can be recruited.
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PREEMPTIVE THERAPY FOR ADENOVIRUS INFEC-
TIONS PREVENTS THE EVOLUTION TO DISSEMI-
NATED DISEASE IN HIGH RISK PAEDIATRIC PATIENTS
AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
TION
Villa A1, Rossi M.R1, Binda S2, Primache V2, Balduzzi
A1, Rovelli A1, Uderzo C1, Longoni D1*; 1Centro
trapianti midollo osseo-Clinica pediatrica, Uni-
versità di Milano-Bicocca, Ospedale San Gerardo,
Monza, Italy; 2Istituto di Virologia, Università degli
Studi di Milano, Italy
BACKGROUND: Adenovirus (AdV) infections after
allogeneic stem cell transplantation (SCT) are asso-
ciated with high transplant-related morbidity and
mortality. AdV infections have been reported in as
many as one/ﬁfth of SCT recipients and in patients
with acquired immunodeﬁciency syndrome (AIDS)
but the incidence of severe AdV disease in paedi-
atrics is increasing in association with growing num-
ber of high risk SCT performed for haematological
malignancies or non-malignant conditions. Risk
factors for AdV infections has been recently re-
ported and include SCT in childhood, immunode-
ﬁciency in the ﬁrst 100 days following transplant,
unrelated and partially matched donor, T and B
cell depletion, myeloablative conditioning regimen
including total body irradiation (TBI), prevention
or treatment of graft-versus-host-disease (GVHD)
with anti-thymocyte globuline (ATG), high immuno-
suppressive conditions including severe peripheral
lymphopenia (<0,3/mmc) and III-IV grade GVHD. In
these patients, AdV infection can be asymptomatic
or cause localized disease such as enteritis, cysti-
tis, upper respiratory tract infection, pneumonitis,
or severe hepatitis and encephalopathy. Invasive
infection was deﬁned as the presence of positive
tests from 2 or more organ systems and/or positive
tests from peripheral blood. Preemptive therapy
of AdV invasive infection with Cidofovir and/or
Ribavirine iv has been started according to this
deﬁnition in the experience of a pediatric bone
marrow transplant unit here reported.
AIMS: Early diagnosis of AdV infection and premp-
tive treatment is the crucial objective to prevent
evolution to disseminated disease in our paediatric
experience.
PATIENTS & METHODS: Since December 1999 to
January 2004, 49/110 transplanted patients, ei-
ther from unrelated (25), or identical (15) and
haploidentical (9) related donor, were monitored
weekly for AdV examining stool, urine, throat spec-
imens and blood by qualitative polymerase chain
reaction (PCR).
RESULTS: 10/49 patients (median age 7 years at
time of SCT) presented AdV invasive infection at a
median time of 55 days after SCT (4 unrelated, 1
identical sibling, 5 haploidentical related donors).
4/10 received TBI, 9/10 patients received ATG as
GVHD prophylaxis or therapy, 7/10 presented GVHD
(6/7 grade I—II, 1/7 grade III). 7/10 were immuno-
suppressed and showing severe lymphopenia. AdV
was detected in stool samples of 9/10 patients,
in urine of 1/10, in throat specimens of 9/10, in
plasma of 2/10 and in peripheral blood lympho-
cytes of 3/10 patients. All patients were symp-
tomatic with fever, cough and/or diarrhoea. Pre-
emptive treatment with Cidofovir (given at 5mg/kg
once weekly for 3 weeks then every 2 weeks) was
started in 9/10 patients (6/10 received 5 doses)
while one patient was treated with Ribavirine be-
cause of low compliance to oral administration of
probenecid before Cidofovir. No Cidofovir-related
toxicity has been demonstrated. 2/10 patients
with AdV in plasma samples developed fatal in-
fection despite prompt treatment with Cidofovir
and withdrawal of immunosupppression; these two
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patients were at particularly high risk because they
received haploidentical T and B depleted allograft
and ATG-prophylaxis, peripheral lymphopenia was
severe, and 1/2 developed acute GVHD resistant to
treatment. One of these two patients died of iso-
lated fulminant hepatic failure with hemorrhagic
cystitis, the other one developed a severe respira-
tory insufﬁciency due to a polmonar localization of
AdV.
CONCLUSIONS: in our paediatric experience, pre-
emptive therapy of early detected AdV infections
prevented progression to disseminated disease in
patients with involvement of two or more organs
and was associated with complete clinical recovery
and viral clearance. On the contrary, the presence
of AdV in blood samples was always associated with
fatal outcome in spite of prompt treatment. Fur-
ther studies will be needed to extend the correla-
tion between the disease and viral serotypes and to
a better identiﬁcation of high risk patients.
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EPSTEIN-BARR VIRUS (EBV) -LYMPHOPROLIFER-
ATIVE DISEASE MOLECULAR MONITORING AND
PREEMPTIVE THERAPY IN HIGH RISK PATIENTS AF-
TER ALLOGENEIC STEM CELL TRANSPLANTATION
IN A PAEDIATRIC CENTER
Grigoli A1, Sangalli H1, Corbellino M2, Balduzzi
A1, Rovelli A1, Uderzo C1, Rossi MR1, Longoni D1*;
1Centro Trapianti Midollo Osseo-Clinica pediatrica,
Università di Milano-Bicocca, Ospedale San Ger-
ardo, Monza, Italy; 2Istituto di Malattie Infettive
e Tropicali, Università di Milano, Ospedale Luigi
Sacco, Milano, Italy
BACKGROUND: EBV is associated with lymphopro-
liferative disease (PTLD) in high risk patients after
allogeneic stem cell transplantation (SCT). Risk fac-
tors for developing PTLD include young age, severe
immunodeﬁciency in the ﬁrst 100 days following
transplant, unrelated or partially matched donor,
T and B cell depletion, myeloablative conditioning
regimen including total body irradiation (TBI), pre-
vention or treatment of graft-versus-host-disease
(GVHD) with anti-thymocyte globuline (ATG), se-
vere peripheral lymphopenia (<0,3/mmc), III—IV
grade GVHD, immunosuppressive treatment (es-
pecially high-dose steroids) and pretransplant EBV
seronegativity. Preemptive therapy with anti-B-cell
monoclonal antibodies (mAbs-rituximab) has been
proven to be efﬁcacious in preventing PTLD. The
experience of a pediatric bone marrow transplant
unit is here reported.
PATIENTS & METHODS: Since January 2002 41 al-
lotransplanted patients, either from unrelated
(16), identical (19) or haploidentical (6) related
donor, were monitored weekly for EBV reactiva-
tion by quantitative real-time polymerase chain
reaction (QT-PCR). Viral reactivation was consid-
ered positive when more than or equal to 30.000
genomes/150000 cells were detected or when
the increase of the viral load was particularly
rapid.
RESULTS: 6/41 patients presented an EBV reactiva-
tion (see table) at a median time of 69 days after
SCT; 3/6 patients presented with active EBV-PTLD
upon examination and were treated with mAbs
(375mg/mq), 2/6 presented asymptomatic re-
activation with normal level of B cells (QT-PCR
higher than 30.000 genomes/150000), and 1/6 was
asymptomatic but was treated with mAbs since
B-cell clonal proliferation was detected. In the 4
patients treated, B-cell clonal proliferation was
shown by FACS analysis. 2/6 patients had received
TBI-containing conditioning regimen, while all pa-
tients had received ATG. 1/6 patient (pts 6) re-
ceived a T and B depleted unrelated SCT. PTLD as-
sociated mortality was 16% notwithstanding prompt
mAbs therapy.
CONCLUSION: our data are consistent with interna-
tional literature showing that weekly quantitative
EBV monitoring and pre-emptive therapy with mAbs
improve outcome in transplanted patients at high
risk of EBV-PTLD.
Pts Age at
SCT
TBI GVHD Days at
reactivation
T cells/mmc at
reactivation
mAbs
(rituximab)
Total
Doses
Outcome Follow-up
1 8 yr N II 63 1100 Y 3 Recovered Died (disseminated
fungal infection)8 mth
2 1 yr N II 78 900 N — Spontaneous
regression
Alive 15 mth after SCT
11 mth
3 13 yr N II 70 4650 Y 2 Died Died for PTLD
4 14 yr Y I 68 1480 Y 4 Recovered Alive 13 mth after SCT
7 mth
5 9 yr Y IV 42 620 N — Spontaneous
regression
Alive 2yrs after SCT
7 mth
6 2 yr N II 74 1360 Y 2 Recovered Alive 2 yrs after SCT
7 mth
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SAFETY OF RECOMBINANT INTERFERON-GAMMA
(IFN-) ADJUVANT THERAPY FOR INVASIVE FUN-
GAL INFECTIONS (IFI) IN THE RECIPIENTS OF
HEMAPOIETIC STEM CELL TRANSPLANTATION
(HSCT)
Safdar A*, Rodriguez G, Omhagari N, Champlin RE;
M.D. Anderson Cancer Center, Houston, Texas 77030
USA
BACKGROUND: Safety of adjuvant IFN- is uncertain
in patients after HSCT.
METHODS: A retrospective evaluation of 32 HSCT re-
cipients who received IFN- during 1998—2003 was
undertaken after IRB approval was obtained. All val-
ues are given in median ± S.D.
RESULTS: Among 18 (56%) male and 14 (44%) female
patients age 41 ± 16 years. Eighteen patients (56%)
had leukemia, 8 (25%) lymphoma and 3 each, had
multiple myeloma and myelodysplastic syndrome.
Twenty-six patients (72%) had received allogeneic
HSCT including a single patient following 2 cord
blood transplants; 6 patients (19%) had autologous
transplants. Twenty-three patients (72%) had re-
ceived prior HSCT. In 21 patients with fungal pneu-
monia, 10 (31%) had possible IFI, 9 (28%) probable
IFI (8 Aspergillus spp included 2 A. fumigatus, 1
each A. ﬂavus, and A. terreus; 1 Paecilomyces),
and 2 patients had deﬁnite invasive pulmonary
aspergillosis. Six patients (19%) had disseminated
mycosis (4 Aspergillus spp. including 2 A. ﬂavus;
A. fumigatus, and A. terreus, 1 each, and 2 with
Fusarium spp. infection). Two patients (6%) had
deﬁnite fungal sinusitis (A. ﬂavus, and Rhizopus).
Candida krusei and C. albicans fungemia occurred
in 1 patient each. IFN- was given as prophylaxis
in a single patient. The duration of IFN- therapy
was 6± 6.5 days (range, 1 to 29 days) and total cu-
mulative dose per patient was 487± 453g (range
35 to 2175g/ml). In 9 (28%), fever was consid-
ered due to IFN-, although 6 were febrile prior
to cytokine therapy. One patient with myalgia and
2 with headache, recovered fully after therapy
was stopped. Two patients with post-IFN- dys-
pnea and 1 with cough had symptoms resolution
despite continued cytokine therapy. In 4 of 5 pa-
tients, abdominal pain was attributed to IFN-, and
in 3 it resolved after treatment was discontinued;
others with nausea, vomiting (n = 3) and diarrhea
(n = 2), had resolution of symptom and IFN- ther-
apy was continued. Three patients had >1.0mg/dl
increase in creatinine after IFN-, in 2 patients
renal function stabilized, IFN- was not stopped,
whereas in one case progressive multi-factorial
acute renal failure warranted hemodialysis de-
spite discontinuation of IFN-. All 7 patients with
pre-IFN- severe neutropenia (<500 cells/mm3)
had neutrophil recovery following cytokine ther-
apy. In 9 individuals with pre-IFN- borderline neu-
tropenia (500—1000 cells/mm3) no improvement
occurred after receiving the cytokine. Recurrent
ALL, and investigational, clofarabine-induced gran-
ulocytopenia were considered probable causes in
4 patients with new onset neutropenia. Pre-IFN-
therapy lymphocytopenia was present in 29 pa-
tients; in 1 patient with Hodgkin’s disease, lym-
phocyte counts recovered 8 days after cytokine
therapy commenced. In only 1 of the remaining 28
patients, IFN- was considered as a potential cause
of progressive lymphocytopenia that occurred af-
ter 3 doses, and resolved 39 days after therapy was
stopped. In 2 patients with thrombocytopenia and
1 with severe anemia that occurred during IFN-
therapy were attributed to mycophenolate and/or
relapsed CML.
CONCLUSION: There was no evidence that adjuvant
IFN- was associated with serious myelotoxicity in
these high-risk stem cell transplant recipients.
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IMPACT OF INTERFERON-GAMMA (IFN-) ADJU-
VANT THERAPY ON GRAFT-VERSUS-HOST DISEASE
(GvHD) IN ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANT (HSCT) RECIPIENTS
Safdar A, Rodriguez G, Ohmagari N, Richard E,
Champlin RE; M.D. Anderson Cancer Center, Hous-
ton, Texas 77030 USA
BACKGROUND: Treatment with IFN- is often ap-
proached with caution in recipients of allogeneic
HSCT due to concerns of GvHD exacerbation.
METHODS: In this retrospective study, we evaluated
26 patients who had received allogeneic HSCT and
IFN- between 1998 and 2003. Institutional Review
Board approved this study. All values are given in
median± standard deviation; total cumulative dose
is abbreviated as c.d.
RESULTS: In 15 (56%) men and 11 (42%) women, age
was 49± 16 years. Fifteen patients (58%) received
matched-related (MRD), six (23%) matched-unrela-
ted (including a case following 2 cord blood trans-
plants), four (15%) partially matched-related,
and one patient (4%) received syngeneic donor
graft. Twenty-one of 26 underwent myeloablative
preparatory conditioning-regimen. Nine patients
each had underlying acute (AML 7; ALL 2) and
chronic leukemia (CML 7, CLL 2). Seven patients
(27%) had lymphoma (4 non-Hodgkin’s) and 1 pa-
tient (4%) had myelodysplastic syndrome (MDS). Six
(23%) patients each were either in complete or par-
tial remission; among 14 patients with post-HSCT
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relapsed or refractory cancer, 1 patient was in
blast crisis. IFN- was given after 260± 323 days
after HSCT (range 10 to 974 days post-transplant).
The total c.d. of IFN- was 546± 453g/ml (range
35 to 2175g/ml) for 7± 6.5 days (range 1 to 29
days). Seven patients (27%) had acute GvHD be-
fore IFN- therapy was commenced. A patient with
grade-II acute disease progressed to chronic GvHD
after IFN- therapy and responded to tracolimus
(c.d. 367mg × 17 days) Steroids (c.d. 1664mg ×
20 days) and Mycophenolate (c.d. 14 g × 7 days).
In fact, 2 patients with severe (grade III and IV)
acute GvHD showed signiﬁcant clinical improve-
ment (grade I) after receiving IFN- therapy. In
others, acute GvHD remained stable. Ten patients
(38%) had chronic GvHD prior to cytokine therapy
was commenced. In 6 of 10, no change in the dose
of immunosuppressive therapy was needed after
treatment with IFN- began (4 with extensive, 1
subclinical and I patient had limited chronic GvHD).
Three patients in fact showed improvement in the
degree of GvHD after IFN- therapy (2 from exten-
sive to subclinical and 1 from extensive to limited).
In 1 patient immunosuppressive dose-adjustment
was needed due to modest progress (no change
in grade) in chronic GvHD; treatment with IFN-
was stopped. A 30 woman with MDS status post
non-myeloablative MRD HSCT presented with a new
onset acute (grade III) GvHD involving the gastroin-
testinal tract. She had received 5 doses of IFN-
for refractory disseminated fusariosis (bloodstream
and cutaneous). IFN- was discontinued; GvHD was
treated with high-dose steroids (500 than 250mg),
tracolimus, anti-thymocyte globulins, and inﬂix-
imab (anti-TNF monoclonal antibodies). The pa-
tient died 2 weeks after IFN- was discontinued,
causes of death included severe refractory fusario-
sis and GvHD.
CONCLUSIONS: There was no evidence that recom-
binant IFN- adjuvant therapy was associated with
increased risk of GvHD in these high-risk allogeneic
stem cell transplant recipients.
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ELIMINATION OF ASPERGILLUS AS A SIGNIFICANT
PATHOGEN IN AN ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANT PROGRAM AFTER INTRO-
DUCTION OF ROUTINE LONG-TERM ITRACONA-
ZOLE PROPHYLAXIS
Winston DJ*, Emmanouilides C, Bartoni K, Schiller
GJ, Paquette R, Territo MC; Stem Cell Transplant
Program, Department of Medicine, UCLA Medical
Center, Los Angeles, CA
Invasive fungal infections are a common cause of
morbidity and mortality in allogeneic hematopoi-
etic stem cell transplant (HSCT) recipients. At many
transplant centers, Aspergillus is the leading cause
of death from fungal infection. In a prospective
randomized trial, we found itraconazole was more
effective than ﬂuconazole for long- term prophy-
laxis of invasive yeast and mould infections after
allogeneic HSCT (9% vs. 25%, p = 0.01). Based upon
these results, we introduced long-term itracona-
zole as routine antifungal prophylaxis in all adult
patients undergoing allogeneic HSCT at UCLA. In-
travenous (IV) itraconazole (200mg IV q12 hrs for
2 days followed by 200mg IV q24 hrs) was started
on day +1 after HSCT and continued until time of
engraftment. After engraftment, patients received
oral itraconazole solution (200mg po q12 hrs) un-
til day +100. After day +100, oral itraconazole
solution was continued in patients still requir-
ing corticosteroids for prevention or treatment of
graft-versus-host disease (GVHD). Both in-patients
as well as outpatients unable to take oral therapy
were returned to IV itraconazole. From Decem-
ber 2001 to December 2003, 73 allogeneic HSCT
patients received routine long-term itraconazole
prophylaxis. These patients were at high-risk for
Aspergillus infection (median age 40 yrs, range
18—64 years; advanced disease 78%; previous HSCT
20%; unrelated donor 41%; high-dose conticos-
teroids for prevention or treatment of GVHD 86%;
grade 2—4 GVHD 45%) None of the 73 patients de-
veloped Aspergillus infection, which is signiﬁcantly
lower that the incidence of Aspergillus infection in
similar matched UCLA allogeneic HSCT patients re-
ceiving ﬂuconazole prophylaxis before 2001 (0% vs
13% p = 0.001). Two cases of candidemia caused by
itraconazole-sensitive organisms (C. albicans and C.
tropicalis) and one case of itraconazole- resistant
candidemia (C. glabrata) were the only invasive
fungal infections. Overall survival was 55%, but no
deaths were related to fungal infection. Except for
nausea and vomiting (19% incidence), itraconazole
was well-tolerated. These results suggest that inva-
sive Aspergillus infections can now be successfully
prevented in high-risk allogeneic HSCT patients by
routine long-term prophylaxis with an azole agent
like itraconazole active against moulds.
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RISK FACTORS FOR POST-ENGRAFTMENT INVASIVE
ASPERGILLOSIS IN ALLOGENEIC STEM CELL TRANS-
PLANTATION
Thursky K*1, Byrnes G2, Grigg A3, Szer J3, Slavin M1;
1Victorian Infectious Diseases Service and National
Health and Medical Research Council Centre of
Clinical Research Excellence in Infectious Diseases,
Royal Melbourne Hospital, Melbourne, Australia,
2Dept of Mathematics and Statistics, University
of Melbourne; 3Bone Marrow Transplant Service,
Department of Clinical Haematology & Medical
Oncology, Royal Melbourne Hospital
The majority of invasive aspergillosis (IA) in allo-
geneic stem cell transplantation (SCT) occurs during
the post-engraftment period. Targeted surveillance
and/or use of newer agents for antifungal prophy-
laxis in high-risk patients may improve outcome if
such patients can be reliably predicted.
OBJECTIVE: The aim was to quantify the effects of
dose-intensity and duration of corticosteroids and
other risk factors for late-onset invasive IA after
allogeneic SCT.
METHODS: Detailed quantitative daily data was
recorded from transplant to last day of follow-up
or death for 217 consecutive allogeneic SCT recip-
ients from 1991 to 1998. Cox proportional hazards
regression was used to evaluate post-engraftment
IA risk with day of suspected onset of probable or
proven IA as failure.
RESULTS: Median duration of follow-up was 330
days. There were 19 cases of IA (overall 8.8%) with
14 post-engraftment infections. In the multivariate
analysis, the use of any ganciclovir within 14—27
days was the strongest risk factor (HR 13.6) inde-
pendent of proven CMV disease, followed by the use
of high dose prednisolone (>1mg/kg/day) within
0—13 days (HR 8.5) and grade 3 or 4 acute GVHD (HR
5.7). Low dose prednisolone (0.25—1mg/kg/day)
within 14—27 days approached signiﬁcance (HR
3.1, 95% CI 0.87—11.07, p = 0.80). Secondary neu-
tropenia was the weakest risk factor (HR 1.3), but
statistically very signiﬁcant. In the univariate anal-
ysis, corticosteroid doses of 0.25—1.0mg/kg/day
for any duration between 2 and 10 weeks demon-
strated prolonged risk for IA.
CONCLUSIONS: This model allows a more individu-
alised ascertainment of risk for IA and assessment
of duration of ongoing risk. Moderate doses of cor-
ticosteroids can confer an increased risk for IA for
extended periods which is almost as marked as that
conferred by higher doses. Reducing ganciclovir use
may reduce the risk of IFI but it would also seem
prudent to target antifungal prophylaxis or surveil-
lance to patients.
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‘‘MINI’’ TRANSPLANTS: ARE THEY ABLE TO MINI-
MIZE INFECTIOUS COMPLICATIONS?
Choi SM*, Lee DG, Park SH, Choi JH, Yoo JH, Shin
WS, Kim CC; Catholic Hemopoietic Stem Cell Trans-
plantation Center, The Catholic University of Korea,
Seoul, Korea
OBJECTIVES: Infectious risks and outcomes after
hematopoietic stem cell transplantation (HSCT)
appear to be in evolution given the introduction of
alternative, non-myeloablative conditioning regi-
mens. Although the timing and types of infections
may differ in non-myeloablative stem cell trans-
plantation (NST, namely, mini-transplantation), the
risk and spectrum of infections in NST are still not
well deﬁned.
METHODS: Medical records of 32 consecutive pa-
tients who had received non-myeloablative allogen-
eic HSCT in Catholic HSCT center between March
1999 and May 2003 were retrospectively analyzed.
RESULTS: There were 21 male and 11 female
patients, with median age of 42 years (range,
23—60). Mean follow-up period was 405 days
(range, 35—1634). Underlying diseases were 15
chronic leukemia, 7 acute leukemia, 5 multiple
myeloma, 4 myelodysplastic syndrome, and 1 se-
vere aplastic anemia. Most of the patients received
ﬂudarabine-base conditioning regimen. The stem
cell source was PBSC in 59.4%, PBSC + BM in 28.1%
and BM in 12.5%. Duration of neutropenia (ANC
< 500/mm3) and profound neutropenia (ANC <
100/mm3) was 11.1 days and 6.3 days, respec-
tively. Incidence of infectious complications was
56.3% (18/32), which was consisted of 7 MDI and
11 CDI. Bacteremia and septic shock was observed
in 4 and 2 patients, respectively (12.5% and 6.3%).
Oral mucositis developed in 65.6% of patients and
most of them showed mild degree of mucositis
with grade I or II. Infectious complications requir-
ing admission during post-engraftment period were
observed in half of the patients. Pre-emptive ther-
apy for cytomegalovirus (CMV) infection was done
in 11 out of 32 patients before day 100 and in 3 out
of 26 patients after day 100. Overall mortality rate
during pre- and post-engraftment period was 6.3%
and 15.6%, respectively. Three out of 32 patients
died due to infectious cause. As graft-versus-host
diasease (GVHD), VOD, and relapse of underlying
diseases interact simultaneously, it was very difﬁ-
cult to ﬁnd out direct cause of death. On multivari-
ate analysis, CMV reactivation before day 100 and
GVHD related admission were the independent risk
factor for the mortality.
CONCLUSIONS: Although the data are preliminary,
NST may decrease the risk of bacterial infections
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associated with mucositis and prolonged neutrope-
nia. However, CMV reactivation was observed in
equal frequency compared with standard HSCT
(2002 KSID symposium, poster no. 41) and con-
tributed signiﬁcantly to morbidity and mortality
after NST. These results will be important to guide
the development of rational preventative strate-
gies in NST recipients.
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VACCINATION AGAINST INFLUENZA FOLLOWING
STEM CELL TRANSPLANTATION
Avetisyan G*1, Rajnavölgyi E2, Hassan M1, Ljungman
P1; 1Department of Hematology, Huddinge Univer-
sity Hospital, Stockholm, Sweden, 2Department of
Immunology, L. Eotvos University, God, Hungary
OBJECTIVE: Patients with hematological disorders
who undergo Stem Cell Transplantation (SCT) ex-
perience a prolonged period of immune deﬁciency,
which increases the risk for bacterial and viral infec-
tions. Inﬂuenza is one of the most common respira-
tory diseases in human; it is potentially lethal in SCT
patients. The response to vaccination is frequently
poor. The aim of this study was to develop moni-
toring techniques for the speciﬁc T-cell response to
inﬂuenza to use in future prospective studies.
METHODS: The project includes 12 healthy con-
trols and 6 SCT patients tested before and 4
weeks after vaccination. The standard 2003/2004
vaccine was used. Peripheral blood lymphocytes
were stimulated with different inﬂuenza peptides.
Three peptides were from the hemagglutinin - H3
HA316—341, H2 HA317—341, and H1-HA306—318.
The HLA-A0201 restricted M1 peptide GILGFVFTL
was used as a control. The ELISPOT assay was used
to determine the number of T-lymphocytes releas-
ing INF-; after stimulation with the peptides. The
intracellular INF-; staining was used to determine
the type of T-cells responding to the peptides. The
number of spots was counted and the responses
before and after vaccination were compared by
Wilcoxon’s rank sum test.
RESULTS: Before vaccination, PBLs from 2/12,
2/12, and 3/12 controls produced IFN-; after stim-
ulation with H3-HA316—341, H2-HA317—341, and
H1-HA306—318, respectively. The corresponding
numbers after vaccination were 8/12, 9/12, and
9/12. The responses were signiﬁcantly stronger
after vaccination for all three peptides (p < 0.02
for all three). By intracellular INF-; staining, it
was suggested that the responses were mediated
by CD4+ cells. Of the 6 SCT patients included in
the study, one patient developed veriﬁed inﬂuenza
A within four weeks of vaccination. After the in-
ﬂuenza A episode, he got a vigorous response both
to the hemagglutinin peptides and the HLA-A0201
restricted peptide. Of the other 5 patients, only
one had developed a positive stimulation response
to the hemagglutinin peptides after vaccination.
CONCLUSIONS: Our results suggest that the ELISPOT
assaymight be used as a complement to serology for
monitoring of inﬂuenza vaccine studies in severely
immunocompromised patients.
042
CYTOMEGALOVIRUS COLITIS WITHOUT POSITIVE
EARLY ANTIGEN TESTS IN PEDIATRIC STEM CELL
TRANSPLANT PATIENTS
Kriván G*, Reményi P, Bátai Á, Lueff S, Réti M, Trem-
mel A, Csomor J, Mihály I, Újhelyi E, Masszi T; Szent
László Hospital, Bone Marrow Transplantation Unit,
Budapest, Hungary
Cytomegalovirus infection represents major mor-
bidity and mortality in allogeneic stem cell trans-
plant recipients. Decreased immunsurveillance
caused by conditioning regimen, graft versus host
disease and immunsuppressive treatment signiﬁ-
cantly increases the risk of virus reactivation. Early
antigen (EA) detection and preemptive therapy
has essential role in prevention of CMV disease.
Within the ﬁrst 100 days after allogeneic trans-
plants immunoﬂuorescent (IF) early antigen (pp65)
detections 2x a week are performed routinely in
St László Hospital. Virus reactivation could be de-
tected reliably with this semiquantitative antigen
test method, however despite of negative EA re-
sults we have diagnosed in 3 patients CMV disease
with organ manifestations (colitis) in last few years.
Diarrhoea was the leading symptom in all cases.
In ﬁrst two pts enteral complaints appeared rela-
tively early after transplant (before the usual time
period for the onset of CMV infection) and other
possible etiologic explanations for diarrhoea (acute
GvH, bacterial infection and alimentary cause)
were presumed. Considering the GvH like skin le-
sions steroid therapy was instituted but severe en-
teral symptoms showed any improvement. Enteral
biopsy was performed; histology and immunocytol-
ogy for CMV EA revealed CMV colitis. After some
days of directed therapy both patients improved
dramatically and recovered. Our third patient was
high risk for CMV infection (severe combined im-
munodeﬁciency, haploidentical, T cell depleted
graft). His severe diarrhoea developed 6 months
after transplant, and after the histological proven
diagnosis of CMV colitis he recovered by foscarnet
therapy.
Diarrhoea in allogeneic stem cell transplant re-
cipients has several possible explanations but the
therapeutic approach differs signiﬁcantly. Because
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sometimes the most reliable diagnostic tools could
be misleading, the invasive diagnostic (e.g. sigma
biopsy and histology) interventions couldn’t be
omitted.
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STEM CELL TRANSPLANTATION FOR THE THERAPY
OF THE INFARCTS AND BURNS
Potapov IV, Rasulov MF, Dolguikh MS*, Zaidenov VA,
Bashkina LV, Grigorjeva AJ, Gigulin AO, Onischenko
NA; Institute of Transplantology, Moscow, Russia
PURPOSE: Stem cell transplantation and the control
the presence and functioning of transplanted cells.
METHODS: The infarcts in the rats were made
by cryoinjury of the hearts. Rat burn wounds
were created by hot metallic plates. Trans-
planted cells were derived from the rat embri-
onic hearts or from bone marrow and cultivated
in DMEM medium during 10—20 days. These cells
were infected by Adv LacZ and after 24 hours
transplanted into rat injuries. Genetic marker
Adv LacZ was human type 5 recombinant aden-
ovirus with deleted E1 region, coding bacterial
-galactosidase and comprised SV-40 promotor. 293
cellular lineage was used for virus ampliﬁcation.
Marked cells were revealed hystochemically by
X-gal.
RESULTS: One week after infarcts embrionic car-
diomyocytes (EC) (N = 3) or mesenchymal stem
cells from bone marrow (MSC) (N = 3) were in-
jected into the scar zone of the hearts. The rats
with transplanted EC received cyclosporin. The
hearts with transplanted cells had the functional
characteristics, assayed by the Neele method,
better as compared to the control group. The
coloured cells were observed during 3 weeks. The
autogenic ﬁbroblastlike MSC (N = 10) or allogenic
embrionic ﬁbroblasts (EF) (N = 10) infected by
AdvLacZ were transplanted to these places. The
presence of transplanted cells were detected af-
ter 1, 3, 7, 15 and 30 days. It was revealed, that
cell transplantation stimulated wounds healing es-
sentially as compared to control (10 rats). Wound
infections were treated better. We have received
also very good results of burns wounds therapy in
clinic.
CONCLUSION: The fetal- and mesenchymal stem
cells transplantation promoted more rapid healing
of the infarcted hearts and burned wounds. The
transplanted cells were visualized in injured animal
sites during 3—4 posttransplant weeks.
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INFECTIONS AMONG ALLOGENEIC AND AUTOLO-
GOUS BONE MARROW TRANSPLANT (BMT) RECIPI-
ENTS IN OTTAWA, CANADA
Gonsalves CL*, McCarthy AE, McDiarmid S, Huebsch
L; University of Ottawa, The Ottawa Hospital
INTRODUCTION/OBJECTIVE: Fever in the neu-
tropenic patient is a medical emergency. Patients
undergoing high-dose therapy and BMT tend to
tolerate infections especially poorly, making ex-
peditious and vigorous empiric therapy a mainstay
of management. The toxicity of the chemotherapy
regimen itself, associated breakdown of normal
mucosal barriers, and immune defects related to
the underlying hematologic disorder, all contribute
to the risk and severity of infection. Current lit-
erature reports an identiﬁable infectious source
in only approximately thirty percent of febrile
neutropenic episodes, the majority of which are
bacterial. Gram negative bacteria are historically
the most commonly identiﬁed of these bacterial
pathogens. However, recently, many centers have
noted a rise in the incidence of Gram positive
infections. Viruses, fungi, and resistant bacterial
organisms are also signiﬁcant pathogens in the
immunocompromised host. The current practice
at our institution is the recommended strategy of
broad spectrum antibiotics that include coverage
against Gram positive and negative organisms, in-
cluding Pseudomonas. We sought to review our
database of BMT recipients over the past 9 years to
identify the incidence of positive cultures, and the
spectrum of pathogens in comparison to currently
reported literature.
METHODS: Clinical characteristics of our trans-
plant population, including presence of, type, and
site of infection, were entered into a computer-
ized database for allogeneic transplants between
1995 and 2003, and for autologous transplants
between 1997 and 2003. The clinical proﬁle of in-
fections were subsequently analyzed. The results
of the patients who had an allogeneic transplant
are summarized below. Ongoing analysis of autol-
ogous transplants is underway, and results will be
presentated at the meeting.
RESULTS: There were 455 autologous transplants
and 278 allogeneic transplants in the aforemen-
tioned years. Among the 260 patients who under-
went the 278 allogeneic transplants, 258 (99.2%)
developed febrile neutropenia. 148 (57.4%) had
286 documented infections: bacterial (61.8%), viral
(28.7%), fungal (7.0%), and other infections (2.5%)
including Pneumocystis. Gram negative bacteria
represented 26.5% of infections as compared to
57.1% Gram positive bacteria and 16.4% anaerobic
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bacteria (all C. difﬁcile infections). The most com-
mon Gram negative bacteria were Escherichia coli,
Pseudomonas spp, and Klebsiella spp. The most
common Gram positive bacteria, in descending or-
der of incidence, were coagulase negative Staphy-
lococcus, Streptococcus viridans, vancomycin
resistant Enterococcus, Enterococcus, Corynebac-
terium, and Staphylococcus aureus. Blood was the
major source of positive cultures (67.5%), followed
by stool (11.2%), lung (8.4%), other (5.9%), urine
(3.5%), central catheter (3.1%), and CSF (0.4%).
CONCLUSIONS: Our centre had a higher incidence
of documented infection amongst our febrile neu-
tropenic patients undergoing allogeneic stem cell
transplantation than reported in the current liter-
ature. While it is now recognized that many cen-
ters have experienced an increase in contribution
of Gram positive infections due to a number of
factors, including long-term indwelling lines, and
chemotherapeutic regimens resulting in mucositis,
in fact the majority of bacterial pathogens from
our allogeneic stem cell transplant population were
Gram positive. Analysis of our autologous stem cell
transplant population is ongoing and will be presen-
tated at the meeting. Given the signiﬁcance of the
emergence of resistant organisms, and the usual
practice of broad spectrum antibiotic use in this
patient population, whether our initial regimens
could be better tailored is an opportune question.
045
PREVOTELLA BUCCAE BACTEREMIA AND FEBRILE
NEUTROPENIA: A CASE REPORT
Fanourgiakis P1*, Georgala A2, Vekemans M2,
Daneau D2, Vandermies A2, Wolff F2, Androulakis
II1, Aoun M2; 1Evangelismos Hospital, Athens &
2Jules Bordet Institute, Brussels
INTRODUCTION: In the resent years, an increasing
number of anaerobic bacteremias of oral origin have
been reported to cause fever in neutropenic cancer
patients. In this context we describe a case of Pre-
votella buccae bacteremia, ﬁrst to our knowledge,
emphasizing the importance of taking into account
oral commensals when selecting antimicrobial reg-
imens.
CASE REPORT: A 24-years-old man with an acute
myeloid leukemia in complete remission underwent
a conditioning regimen consisting of melphalan, ﬂu-
darabine, antithymocyte globulin and total body ir-
radiation, before the allogeneic bonemarrow trans-
plantation. As infection prophylaxis, ciproﬂoxacin,
trimethoprim/sulfamethoxasole, itraconazol and
acyclovir were given. On day 10 post-chemotherapy,
the patient developed fever (38.3 ◦C) without rig-
ors and signs of hemodynamic decompensation.
He complained also of dysphagia and retrosternal
pain. Mild oral mucositis was present with probable
esophagitis but esophagoscopy was not performed.
Severe neutropenia (<50/mm3) and thrombocy-
topenia (11,000/mm3) were present. Urine exam-
ination and chest X-ray were normal. Three sets
of blood cultures were drawn and treatment with
piperacillin/tazobactam 4 gr qid IV was initiated.
The stem cells were infused the day after and two
days later the temperature normalized. All blood
cultures revealed Prevotella buccae.
DISCUSSION: Prevotella, along with Bacteroides
spp., are numerically the most prevalent organisms
of the normal human bacterial ﬂora. Prevotella
spp., usually as part of a mixed ﬂora, are impli-
cated in dental, oropharyngeal, pleuropulmonary,
abdominal and gynecological infections but they
are not a frequent cause of bacteremia. Prevotella
buccae, a non-pigmented, pentose-fermenting
species, is a commensal of oropharynx and is mainly
involved in dental, oral and respiratory infections.
Searching in MEDLINE identiﬁed only one case of
clinically signiﬁcant bacteremia due to Prevotella
buccae. It is well known that normal oral commen-
sals, both aerobic and anaerobic, gain access to
the blood stream through breaches of the mucosa
in cancer neutropenic patients. The selective pres-
sure of quinolone prophylaxis and the profound
and prolonged neutropenia along with the oral le-
sions, result in the emergence of new pathogens.
Some of these germs, considered of low virulence,
proved to be able to cause clinically signiﬁcant
bacteremias. It is the ﬁrst time that Prevotella buc-
cae bacteremia is recognized as a cause of febrile
neutropenia. All pre-mentioned predisposing fac-
tors were present. No special symptoms and signs
were detected, and the evolution was benign. In
summary, one more oral anaerobe i.e. Prevotella
buccae, proved to be a potential pathogen in gran-
ulocytopenic patients and it is probable that this
can be the case and of other mouth commensals as
well. This emphasises the need of measures to pre-
vent and/or control mucositis and that clinicians
need to be aware of the spectrum and susceptibil-
ity patterns of these germs.
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CIDOFOVIR LOCAL TREATMENT OF ADENOVIRUS
HEMORRHAGIC CYSTITIS IN A BMT RECIPIENT
Fanourgiakis P*, Georgala A, Vekemans M, Triffet A,
Martiat P, Snoeck R, Wollants E, Van Ranst M, Aoun
M; Infectious disease department, Institute Jules
Bordet, Brussels
INTRODUCTION: Hemorrhagic cystitis (HC) inci-
dence in BMT recipients varies from 10% to 70%. A
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biphasic occurrence is observed. The late form has
a protracted course, severe symptoms and is asso-
ciated with Adenovirus (AV) and Polyomavirus BK
(BKV) shedding. Dysuria, hematuria, lumbar pain
and increase of creatinine are the main manifes-
tations. No local or systemic treatment, proved to
be adequate for severe HC.
CASE REPORT: A 34 year-old man with a four years
history of CML, Ph+, was admitted because of
hematuria, renal insufﬁciency and encephalopathy.
Four months before, he beneﬁted from a familial
haplo-identical BMT. Conditioning regimen included
ﬂudarabine, melphalan, antithymocyte globulin
and TBI. Acute GVHD occurred on day 27 post-BMT,
necessitating the combination of CsA, mycophe-
nolic mofetil (MMF) and methylprednisolone (MP).
A complete morphological and molecular remis-
sion and a 100% donor chimerism were attested
in a bone marrow aspirate on day 30. On day 50
post BMT because of CMV reactivation, ganciclovir
I.V. was initiated. At the same time, microscopic
hematuria was shown associated with positive
PCRs for BKV in the urine. The patient was dis-
charged on day 90 while he was yet on MP, MMF
and CsA. Urine sample taken just before discharge
showed positive AV antigen detection and posi-
tive viral culture with an AV cytopathogenic effect
in addition to positive PCR for BKV. Upon his last
admission antigen detections and viral cultures
for AV were positive but BKV PCR was repeatedly
negative. Bladder continuous irrigation with saline
was initiated without improvement. Because of re-
nal failure (creatinine: 2.3mg/dl) we decided to
administer cidofovir locally. A dose of 5mgr/kgr
diluted in 100ml saline was instilled in the bladder
for one hour. HC was markedly improved during
the following days. Blood clotting disappeared and
urine cleared progressively. AV culture and anti-
gen became negative on two consecutive samples.
Creatinine level ameliorated (1.7mg/dl). 12 days
later the patient developed sepsis due to Klebsiella
oxytoca and died from multiple organ failure.
DISCUSSION: In immunocompromised patients, the
spectrum of manifestations of AV ranges widely
from asymptomatic excretion to fatal disseminated
disease, including interstitial pneumonia, fulmi-
nant hepatitis and hemorrhagic diathesis. The inci-
dence of AV-associated hemorrhagic cystitis varied
between 1 to 8.4%. The risk factors identiﬁed so
far are GVHD and its immunosuppressive therapy,
non familial allogeneic BMT, T-cell depleted BMT
and conditioning regimen with ﬂudarabine. Differ-
ent strategies have been advocated for the man-
agement of severe intractable HC but there is no
established antiviral therapy. Cidofovir has in vitro
activity against BKV and AV. However its systemic
use in BMT has been hampered by the signiﬁcant
nephrotoxicity of this drug. To our knowledge this is
the ﬁrst case of cidofovir bladder instillation which
could be an alternative to intravenous administra-
tion so that the drug will not be absorbed through
inﬂamed bladder mucosa. A potential complication
of i.v. use of cidofovir is nephrotoxicity, however,
in our case; local treatment was followed by an
amelioration of creatinine level. No blood concen-
trations of cidofovir have been performed. There
was a clinical improvement with relief of all symp-
toms associated with HC and AV was not detected
any more in urine.
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FUNGAL INFECTIONS IN ALLOGENEIC NON-MYELO-
ABLATIVE STEM CELL TRANSPLANT RECIPIENTS
Narreddy S, Mellon-Reppen S, Abidi MH, Klein J,
Peres E, Chandrasekar PH*; Karmanos Cancer Insti-
tute andWayne State University School of Medicine,
Detroit, Michigan, USA
BACKGROUND: Non-myeloablative technique of al-
logeneic stem cell transplantation is recent and in-
creasingly popular; data regarding fungal infections
are limited.
METHODS: We examined our data on fungal in-
fections in patients undergoing non-myeloablative
transplantation (NMT) during Sep 2000—Sep 2003.
RESULTS: Forty nine patients (men 29, mean age
50.5 y; women 20, mean age 45.2 y) underwent
non-myeloablative transplantation (NMT) during
Sep 2000—Sep 2003 (number of patients: 3-2000;
20-2001; 14-2002; 12-2003). Major underlying dis-
eases were renal cell carcinoma (15), non-hodgkins
lymphoma (9), and myeloma (8). Of 49 patients,
22 received matched unrelated donor stem cells.
Conditioning regimens were ﬂudarabine with either
cyclophosphamide (36 pts) or total body irradiation
(13 pts). Most (46/49) received peripheral blood
stem cells. Mean duration of neutropenia was 6.8
days (range 0—16). Two patients had a previous fun-
gal infection. All patients received ﬂuconazole as
prophylaxis during pre-engraftment phase. Thirty
eight of 49 patients (76%) developed graft verus
host disease and among these 32 pts received high
dose corticosteroids (greater than 1mg/kg). Thirty
patients with graft versus host disease on corti-
costeroids received antifungal prophylaxis (ﬂu-
conazole 23; itraconazole 6; amphotericin B lipid
complex 1). Seven patients (14%) had documented
fungal infection; three had candida infection (2
esophagus; 1 thrush); invasive aspergillosis (A.
fumigatus 2, A. niger 1, A. sp 1) occurred in 4 pa-
tients (disseminated 2, pulmonary 2). Moderate to
severe graft versus host disease and CMV infection
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were associated factors. Three of 4 patients with
aspergillosis succumbed to the infection. Overall,
26 of 49 transplanted patients (52%) died.
CONCLUSIONS: Frequency of fungal infections in
nonmyeloablative transplant recipients is similar to
that seen in myeloablative transplant recipients.
Invasive aspergillosis is the most common cause
of death due to fungi among nonmyeloablative
transplant patients.
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CYTOMEGALOVIRUS (CMV) INFECTION IN ALLO-
GENEIC NON-MYELOABLATIVE STEM CELL TRANS-
PLANT RECIPIENTS
Narreddy S, Mellon-Reppen S, Abidi MH, Klein J,
Peres E, Chandrasekar PH*; Karmanos Cancer Insti-
tute andWayne State University School of Medicine,
Detroit, Michigan, USA
BACKGROUND: Non-myeloablative technique of al-
logeneic stem cell transplantation is recent and in-
creasingly popular; data regarding CMV infection
are limited.
METHODS: We examined our data on CMV infection
in patients undergoing non-myeloablative trans-
plantation (NMT) during Sep 2000—Sep 2003.
RESULTS: Forty nine patients (men 29, mean age
50.5 y; women 20, mean age 45.2 y) underwent
non-myeloablative transplantation (NMT) during
Sep 2000—Sep 2003 (Number of patients: 3-2000;
20-2001; 14-2002; 12-2003). Major underlying dis-
eases were renal cell carcinoma (15), non-hodgkins
lymphoma (9), and myeloma (8). Of 49 patients,
22 received matched unrelated donor stem cells.
Conditioning regimens were ﬂudarabine with either
cyclophosphamide (36 pts) or total body irradiation
(13 pts). Most (46/49) received peripheral blood
stem cells. Mean duration of neutropenia was 6.8
days (range 0—16). Twenty three of 49 patients
were CMV seropositive; two received prophylaxis
against CMV. CMV antigen (pp65) test was routinely
done once weekly. CMV antigenemia occurred in
23 patients (with viremia in 10), 8 of whom were
seropositive and 2 seronegative, after a median du-
ration of 47 days (range 22—726) from transplant.
Antigenemia after 100 days occurred in 5 patients.
Three of 23 patients with antigenemia developed
CMV disease. Eight of 23 patients with antigenemia
had received stem cells from unrelated donors. CMV
antigenemia was of low level in most patients with
prompt response to intravenous ganciclovir. Nine
patients developed recurrent antigenemia, 4 of
them despite prophylaxis. Of the total 49 patients
transplanted, 26 died; none due to CMV disease.
CONCLUSIONS: Our preliminary data demonstrate
that CMV infection is common in NMT recipients;
routine surveillance and pre-emptive therapy with
ganciclovir are effective in preventing CMV disease.
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A COMPARISON OF BLOODSTREAM INFECTIONS IN
ALLOGENIC AND AUTOLOGOUS BONE MARROW
TRANSPLANTS (BMT)
Haider S*1, Phillips C2; 1McMaster University Fac-
ulty of Medicine, Division of Infectious Diseases and
2Dept of Medicine
BACKGROUND: Nosocomial surveillance systems
have been important in documenting changes in
the pattern of bloodstream infections in hospi-
talized patients. Such surveillance systems in the
last 10 years have clearly documented the emer-
gence of Gram positive organisms over Gram neg-
ative organisms as leading causes of nosocomial
bacteremias. However the epidemiology of blood-
stream infections in hospitalized allogenic and
autologous transplant patients has been less well
studied. Understanding the epidemiology of blood-
stream infections in BMT patients, will help guide
empirical therapy and improve outcomes. Meth-
ods: We reviewed microbiological records for all
positive bloodstream episodes in autologous trans-
plant patients hospitalized b/w 1998—2002 and
allogenic tranplant patients hospitalized b/w Jan
1997—March 2002 at the Hamilton Health Sciences
Center, a tertiary academic center in Canada. The
Hamilton Health Sciences Center is made up of four
hospitals, where autologous and allogenic trans-
plants are carried out at different hospital sites.
We deﬁned new episodes of bloodstream infections
as all positive blood cultures with different iso-
lates, and all positive blood cultures with similar
isolates separated by at least 7 days, and in cases
of polymicrobial infections each isolate counted as
a separate episode of bloodstream infection.
RESULTS: B/W Jan 1997—Mar 2002 110 allogenic
transplants were performed, complicated by 47
episodes of bloodstream infections in 39 patients
(35% of patients) or 1.2 episodes of bloodstream
infections/patient. The percent of Gram positive
versus Gram negative isolates was respectively
79% vs 19%, with coagulase negative staphylococ-
cus as the most common isolate. In comparison
b/w 1998—2002 184 autologous transplants were
performed, complicated by 79 episodes of blood-
stream infections in 52 patients (28% of patients)
or 1.5 episodes of bloodstream infection/patient,
with 76% Gram positive and 19% Gram negative,
again coagulase negative staphylococcus emerged
as the most common isolate.
CONCLUSIONS: In our review of microbiological
records, rates of bloodstream infections were
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similar in autologous and allogenic transplant pa-
tients. This is likely due to the fact that most of
these infections occurred early in the post tran-
plant period, where neutropenia puts both popula-
tions at risk. It is also clear that the epidemiology
of nosocomial bloodstream infections in BMT pa-
tients, is similar to that seen in other hospitalized
patients favoring Gram positive over Gram nega-
tive organisms. Such data will help guide empirical
therapy in this high risk subgroup of patients, and
the introduction of infection control practices to
improve clinical outcomes.
050
TRYPANOSOMA CRUZI INFECTION IN PATIENTS
SUBMITTED TO HEMATOPOIETIC PROGENITORS
CELLS TRANSPLANT
Cobos M*, Bitar N, Napal J, Bordone J, Milone J;
ITMO La Plata, Argentina
INTRODUCTION: Infection with Trypanosoma cruzi
is an endemic illness in Latin America. The chronic
form of the illness in most of the population re-
mains without symptoms. In the patients submit-
ted to hematopoietic progenitor cells transplant,
the immunodeﬁciency might reactivate the para-
site, giving a fatal outcome.
OBJECTIVE: To review Trypanosoma cruzi infec-
tion in hematopoietic progenitor cell transplant
patients.
METHODS: Between the years 1993 and 2003, in our
institute 331 transplants were performed, being 218
autologous and 113 allogeneics. They all were eval-
uated, before the procedure, along their donors,
for Trypanosoma cruzi infection.
RESULTS: Six patients were positive, 2 autolo-
gous transplants (0.9%) and 4 allogeneic trans-
plants (3.5%). The Strout method was performed
weekly for 3 months after the transplant. In 1
patient, the Strout method was positive on the
88th day. The patient had acute promyelocytic
leukemia, treatment for graft-versus-host disease,
cytomegalovirus infection and suspected invasive
mycoses. Treatment with Benznidazol 5mg/kg/day
was started; parasites were not present in blood
1 week later. The total treatment was for three
months.
CONCLUSIONS: The Strout method is a good mea-
surement to detect reactivation of the parasite in
both types of transplant and to initiate opportune
and effective therapeutics.
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CLINICAL AUDIT IN BONE MARROW TRANSPLANT
UNIT. THE EFFECTOF CHANGE IN ANTIBIOTIC PRO-
PHYLAXIS ON RESISTANCE TRENDS
Sharma R*, Anson J, Whitaker R; Royal Liverpool
University Hospital, UK
OBJECTIVES: Bone marrow transplant (BMT) reci-
pients receive antibiotic prophylaxis with ciproﬂo-
xacin (CIP) - to reduce the occurrence of bacter-
aemia with Gram-negative rods (GNR). Colistin
(COL) is used, at several centers, in combination
with CIP to reduce the risk of emergence of resis-
tance. This clinical audit was carried out following
discontinuation of use of colistin for prophylaxis
in BMT recipients to establish any emergence of
antibiotic resistance in GNR.
METHODS: Antimicrobial susceptibility proﬁles of
bacterial blood cultures isolates from BMT re-
cipients processed between January 2000—April
2003 (CIP + COL period). The preliminary data
(May 2003—January 2004) of this ongoing au-
dit after cessation of use of COL (CIP alone
period).
RESULTS: During the CIP + COL period — enter-
obacteriacea (NIL), CIP sensitive Pseudomonas
spp (3), CIP resistant Serratia marcescens (1) and
Stenotrophomonas maltophilia (7), vancomycin
sensitive Enterococcus faecium (13) and Entero-
coccus faecalis (2), and vancomycin resistant Ente-
rococcus faecalis — VRE (1) were isolated. During
CIP only period - ciproﬂoxacin resistant E. coli (2),
CIP sensitive Serratia marcescens (1) and Pseu-
domonas spp (1), CIP resistant Stenotrophomonas
maltophilia (2), vancomycin sensitive Enterococ-
cus faecalis (3), and VRE (1). No changes were
observed in MRSA, streptococcal, CNS, diphtheroid
isolates, etc.
CONCLUSIONS: The use of ciproﬂoxacin alone was
associated with 2 patient episodes of ciproﬂoxacin
resistant E. coli bacteraemia. Prophylaxis with
ﬂouroquinolones alone in BMT recipients has been
shown to select for resistant bacteria. Guleri
2001, have shown an increase (2% - 1997 to 21%
- 2001) of CIP resistant enterobacteriacea with
use of ciproﬂoxacin alone & Kibbler, et al. 2001,
have shown a reduction using CIP + COL in com-
bination for prophylaxis. This is an ongoing audit
and current trends may result in the reinstitu-
tion of using COL in combination with CIP for
prophylaxis.
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PREVALENCE OF RESPIRATORY VIRUS INFECTION
IN BMT RECIPIENTS DURING THREE CONSECUTIVE
YEARS IN SÃO PAULO, BRAZIL
Machado CM*, Vilas Boas LS, Rocha IF, Pannuti CS;
Virology Laboratory, Instituto de Medicina Tropical
de São Paulo and BMT Division, Discipline of Hema-
tology, University of São Paulo Medical School, São
Paulo, Brazil
OBJECTIVES: Evaluate the prevalence of respi-
ratory syncytial virus (RSV), inﬂuenza A and B,
parainﬂuenza and adenovirus infection among BMT
recipients during three consecutive years.
METHODS: Direct immunoﬂuorescence assay (DFA)
(Imagen®, DAKO, UK) performed in nasopharyngeal
washes taken from all BMT recipients with respira-
tory symptoms year round.
RESULTS: In 2001, 59 of 140 pts (42.1%) with res-
piratory symptoms tested positive. In 2002, 56
of 206 pts tested positive (27.2%) and in 2003,
34 of 174 pts (19.5%) tested positive. The preva-
lence of RSV infection in pts who tested positive
by DFA was quite similar during the study period
(40.7%, 41% and 44%, respectively). Oppositely, In-
ﬂuenza A, inﬂuenza B and parainﬂuenza infection
prevalence varied greatly in consecutive years:
Inﬂuenza A prevalence was 28.8%, 5.3% and 35%
in 2001, 2002 and 2003, respectively. Inﬂuenza
B prevalence was 37.3% in 2001, 10.7% in 2002
and 5.8% in 2003. Parainﬂuenza infection preva-
lence was 15.2% in 2001; 58.9% in 2002 and 50% in
2003. Interestingly, among patients belonging to
two consecutive cohorts (2001—2002; 2002—2003)
only one patient presented RSV reinfection within
a 112 year interval. Considering that seasonal ex-
posure to RSV was similar during this period, this
observation may reﬂect long lasting RSV immu-
nity acquired during the infection in the previous
year.
CONCLUSIONS: The prevalence of RSV infection
among BMT recipients with respiratory symptoms
was quite similar in consecutive years. Prospective
studies evaluating the dynamics of RSV antibod-
ies after BMT and the protective role of humoral
immunity should be investigated in this population.
